Luis Paz-Ares, MD, PhD
Enriched profileHead (Jefe de Servicio) of the Medical Oncology Service, Hospital Universitario 12 de Octubre, Madrid, since January 19, 2015 · Hospital Universitario 12 de Octubre
Luis Paz-Ares is Head (Jefe de Servicio) of the Medical Oncology Service, Hospital Universitario 12 de Octubre, Madrid, since January 19, 2015 at Hospital Universitario 12 de Octubre. OpenAlex indexes 1,385 publications with 95,865 citations (h-index 120); ClinicalTrials.gov lists 1 registered study with this person as an investigator. Clarivate lists Luis Paz-Ares as a Highly Cited Researcher (Clinical Medicine, 2019).
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Luis Paz-Ares is Head (Jefe de Servicio) of the Medical Oncology Service, Hospital Universitario 12 de Octubre, Madrid, since January 19, 2015. The public record shows 1,385 publications with 95,865 citations (h-index 120), centered on Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Cancer Immunotherapy and Biomarkers. It also documents an investigator role on 1 registered clinical trials.
- Most recent indexed publication: 2026 · Nature medicine
- Top research focus: Lung Cancer Treatments and Mutations
- 1 registered trials on ClinicalTrials.gov
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 32 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 522.
Clinical & industry
trials, payments and federal fundingNot shown. No U.S. clinical registration on file.
Federally funded research awards.
Public positions
sourced statements on record- Appeared before the Spanish Senate Health Commission (Comisión de Sanidad, Senado)
May 21, 2024, on World Clinical Trials Day …
2024verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →congreso.es ↗
This is a research profile, built on the published record. There's no U.S. clinical registration (NPI) on file, so facts that hang off one (clinical specialty, industry payments) aren't shown. We'd rather leave a gap than guess. Why? →
Contact
An office address from a public listing. This research profile has no federal registry record to draw from.
Office address
Hospital Universitario 12 de Octubre, Servicio de Oncología Médica, Av. de Córdoba, s/n, 28041 Madrid, Spain
Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 1 registered study on ClinicalTrials.gov. The most recent:
Industry payments
Not shown. This person has no U.S. clinical registration (NPI) on file, so we can't reliably tie industry payments reported to CMS to them. We'd rather leave a gap than guess. Why? →
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer.
Clinical cancer research
Article2026 - Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.
Journal of clinical oncology
Clinical Trial2026 - NOTCH1 intracellular domain stabilization by MDM2 plays a major role in NSCLC response to platinum.
EMBO molecular medicine
Article2026
Most-cited works
by citation count (OpenAlex)- 01
- 03Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer4,548 citations2017
- 04Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer3,645 citations2018
- 05Lung cancer: current therapies and new targeted treatments3,361 citations2016
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Other
produccioncientifica.ucm.es/investigadores/145401/detalle
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →produccioncientifica.ucm.es ↗ - Google Scholar
scholar.google.com/citations
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholar.google.com ↗ - ResearchGate
researchgate.net/lab/Luis-Paz-Ares-Lab
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Instagram
instagram.com/p/DOixRbXjYlO
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →instagram.com ↗ - Instagram
instagram.com/p/DRj1vSJjCS3
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗ - Instagram
instagram.com/seom_oncologia/reel/CyqKWNCNRnF
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →globaloncologyacademy.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →comunidad.madrid ↗
- Master's in Clinical Pharmacology
University of Glasgow (1993–1995), completed as ESMO Research Fellow at the Beatson Oncology Centre
1995verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →globaloncologyacademy.org ↗ - PhD in Medicine
Universidad Autónoma de Madrid, April 1993, with "Outstanding cum laude" distinction; thesis: "Eventos neoplásicos tardíos en tumores quimiocurables …
1993verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →globaloncologyacademy.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →seaponline.es ↗
Editorial & leadership roles
journal and society appointments- President of ASEICA (Asociación Española de Investigación sobre el Cáncer)
two-year term beginning January 2021 through 2022, succeeding Xosé Bustelo; now past-president
2022verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aseica.es ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →comunidad.madrid ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →comunidad.madrid ↗
Highly Cited Researcher
Clarivate's annual list, by award category and year- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗
Awards & honors
honors on the public record- Corresponding Academic Member (Académico Correspondiente) of the Real Academia de Farmacia de Galicia
inducted May 15, 2025, with inaugural lecture "Small Cell Lung Cancer: From Biology to Treatment"
2025verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →academiadefarmaciadegalicia.gal ↗ - Prize of the International Association for the Study of Lung Cancer (IASLC)
September 2024, honoring achievements in the study of small cell lung cancer
2024verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →comunidad.madrid ↗ - Lilly Foundation Award for Clinical Biomedical Research (Clinical Research category)
2017, for work on the molecular biology of lung cancer and its treatment
2017
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →academiadefarmaciadegalicia.gal ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →globaloncologyacademy.org ↗
- Associate/Tenured Professor of Medicine
Faculty of Medicine, Universidad Complutense de Madrid
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →comunidad.madrid ↗
Media & interviews
press, podcasts and appearances- Print/online feature interview
InnovaSpain, "Llegar al 70% de supervivencia en cáncer en 2030 es un objetivo ambicioso pero realista"
2030verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →innovaspain.com ↗ - Audio interview
AudioMedica/Audio Journal of Oncology, "Longer Survival Among Patients with Extensive Stage Small Cell Lung Cancer Treated with Lurbinectedin Maintenance", ASCO 2025
2025provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →audiomedica.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →imdb.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute
Julie Brahmer, MD
Johns Hopkins University School of Medicine
Enriqueta Felip, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center